- Home
- GROW vs JSPR Comparison
GROW vs JSPR Comparison
Compare GROW & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | JSPR |
|---|---|---|
| Founded | 1968 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 26.3M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GROW | JSPR |
|---|---|---|
| Price | $2.83 | $0.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 10.9K | ★ 358.0K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | ★ 900.00 | 19.22 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $14,399,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.92 | ★ N/A |
| Revenue Growth | ★ 32.77 | N/A |
| 52 Week Low | $2.23 | $0.32 |
| 52 Week High | $3.65 | $2.69 |
Technical Indicators
Market Signals| Indicator | GROW | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 29.45 | 32.39 |
| Support Level | $2.45 | $0.42 |
| Resistance Level | $2.75 | $0.67 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 10.53 | 7.71 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.